Watson Pharmaceuticals Acquires Eden Biodesign

February 4, 2010

Watson Pharmaceuticals has acquired Eden Biodesign for $15 million.

US-based Watson Pharmaceuticals, Inc., has acquired the UK contract manufacturer Eden Biodesign for approximately $15 million. As a result of the acquisition of the Arrow Group Watson had previously acquired approximately 36% of Eden by acquiring the Arrow Group in December 2009.

Eden, which will be part of Watson’s Global Brands Division, will maintain its established contract services model, while providing Watson with biopharmaceutical development and manufacturing capabilities.

According to the deal, Watson will take control of Eden’s biologics production plant in Liverpool as well as its contract development and manufacturing business. Both Eden Biodesign's management and staff remain unchanged and Eden Biodesign will continue to operate independently under it's current name and business model as a subsidiary of Watson Pharmaceuticals' Global Brands Division.

Eden Biodesign is a globally-integrated biopharmaceutical company offering consultancy, biopharmaceutical design, process development, and cGMP manufacturing services to biotech and pharmaceutical clients around the world.

Watson Pharmaceuticals, Inc. is a global specialty pharmaceutical company, which is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.